CN115003305A - 使用莱博雷生治疗失眠 - Google Patents

使用莱博雷生治疗失眠 Download PDF

Info

Publication number
CN115003305A
CN115003305A CN202080094379.0A CN202080094379A CN115003305A CN 115003305 A CN115003305 A CN 115003305A CN 202080094379 A CN202080094379 A CN 202080094379A CN 115003305 A CN115003305 A CN 115003305A
Authority
CN
China
Prior art keywords
pharmaceutically acceptable
child
acceptable salt
pugh
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080094379.0A
Other languages
English (en)
Chinese (zh)
Inventor
A·萨特林
M·默林
I·兰德里
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanitary Material R&d Management Co ltd
Original Assignee
Sanitary Material R&d Management Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanitary Material R&d Management Co ltd filed Critical Sanitary Material R&d Management Co ltd
Publication of CN115003305A publication Critical patent/CN115003305A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN202080094379.0A 2019-12-20 2020-12-18 使用莱博雷生治疗失眠 Pending CN115003305A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962951638P 2019-12-20 2019-12-20
US62/951,638 2019-12-20
PCT/US2020/065891 WO2021127359A1 (en) 2019-12-20 2020-12-18 Use of lemborexant for treating insomnia

Publications (1)

Publication Number Publication Date
CN115003305A true CN115003305A (zh) 2022-09-02

Family

ID=74191874

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080094379.0A Pending CN115003305A (zh) 2019-12-20 2020-12-18 使用莱博雷生治疗失眠

Country Status (11)

Country Link
US (1) US20230051268A1 (https=)
EP (1) EP4076463A1 (https=)
JP (2) JP2023508011A (https=)
KR (1) KR20220119065A (https=)
CN (1) CN115003305A (https=)
AU (1) AU2020408557A1 (https=)
BR (1) BR112022012246A2 (https=)
CA (1) CA3165481A1 (https=)
MX (1) MX2022007304A (https=)
TW (1) TW202137986A (https=)
WO (1) WO2021127359A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024305901A1 (en) * 2023-06-29 2026-02-12 Janssen Pharmaceutica Nv Method of treating depression using seltorexant

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016063995A1 (en) * 2014-10-23 2016-04-28 Eisai R&D Management Co., Ltd. Compositions and methods for treating insomnia

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0828751A4 (en) 1995-05-05 1999-01-20 Human Genome Sciences Inc HUMAN NEUROPEPTIDE RECEPTOR
US6309854B1 (en) 1996-12-17 2001-10-30 Smithkline Beecham Corporation Polynucleotides encoding ligands of the neuropeptide receptor HFGAN72
US5935814A (en) 1997-04-30 1999-08-10 Smithkline Beecham Corporation Polynucleotides encoding HFGAN72Y receptor
US6020157A (en) 1997-04-30 2000-02-01 Smithkline Beecham Corporation Polynucleotides encoding HFGAN72X receptor
US6166193A (en) 1997-07-25 2000-12-26 Board Of Regents, University Of Texas System Polynucleotides encoding MY1 receptor
AU2011304285B2 (en) 2010-09-22 2015-01-29 Eisai R&D Management Co., Ltd. Cyclopropane compound
BR112014019909B1 (pt) 2012-02-17 2020-01-28 Eisai R&D Man Co Ltd processo para produção de compostos úteis como antagonistas do receptor de orexina-2
CA3051830A1 (en) * 2017-01-27 2018-08-02 Neurocrine Bioscienes, Inc. Methods for the administration of certain vmat2 inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016063995A1 (en) * 2014-10-23 2016-04-28 Eisai R&D Management Co., Ltd. Compositions and methods for treating insomnia

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LAURA GENN: "Lemborexant Shows Promise for Sleep Disorders", HCP LIVE NETWORK, pages 1 - 3 *

Also Published As

Publication number Publication date
BR112022012246A2 (pt) 2022-08-30
JP2025160480A (ja) 2025-10-22
EP4076463A1 (en) 2022-10-26
TW202137986A (zh) 2021-10-16
JP2023508011A (ja) 2023-02-28
CA3165481A1 (en) 2021-06-24
WO2021127359A1 (en) 2021-06-24
KR20220119065A (ko) 2022-08-26
MX2022007304A (es) 2022-08-22
AU2020408557A1 (en) 2022-08-11
US20230051268A1 (en) 2023-02-16

Similar Documents

Publication Publication Date Title
RU2703297C2 (ru) Композиции и способы для лечения бессонницы
Banarer et al. Sleep-related hypoglycemia-associated autonomic failure in type 1 diabetes: reduced awakening from sleep during hypoglycemia
KR20200085837A (ko) 유전적 간질 질환 치료에 사용하기 위한 가낙솔론의 용도
US12465583B2 (en) Methods of treatment using an mTORC1 modulator
TW202142229A (zh) 治療雷葛氏症候群之病患的方法
TW201740952A (zh) 晝夜節律睡眠障礙之治療方法
AU2021205892A1 (en) A method for enhancing the pharmacokinetics or increasing the plasma concentration of methyl 3-((methylsulfonyl)amino)-2-(((4-phenylcyclohexyl)oxy)methyl)piperidine-1-carboxylate or a salt thereof with an inhibitor of cytochrome P450
WO2006017892A1 (en) Methods for improving cognitive functioning
CN120641090A (zh) 向哺乳期女性施用索安非托的方法
AU2026201519A1 (en) Lemborexant for treating sleep issues
JP2025160480A (ja) 不眠症を治療するためのレンボレキサントの使用
AU2022340824A1 (en) Methods and compositions for ameliorating biomarkers associated with cardiovascular risk using (r)-2-amino-3-phenylpropyl carbamate
GB2617823A (en) A cannabidiol oil and uses thereof
Ellis Theophylline
RU2844395C2 (ru) Лемборексант для лечения проблем со сном
Barrouq et al. Escalating BMI Associated With the Complex Pharmacology of Propranolol: A Case Report
EP3989976A1 (en) Lemborexant for treating sleep issues
JP2025116005A (ja) 睡眠問題の治療のためのレンボレキサント
WO2020263331A1 (en) Lemborexant for treating sleep issues
WO2026052068A1 (zh) 药物组合物的用途
WO2023143364A1 (zh) 一种血小板生成素受体激动剂的给药方案
WO2020240550A1 (en) Cannabidiol for treating type 1 diabetes mellitus
Tremor NEUROLOGICAL SLEEP DISORDERS
Wise et al. Effects of smoking on insulin sensitivity, insulin clearance, and time-action profile following regular human insulin
NZ787958A (en) Methods of treating circadian rhythm sleep disorders

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination